Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.44
Dollar change
+0.44
Percentage change
11.00
%
Index- P/E- EPS (ttm)-1.81 Insider Own49.43% Shs Outstand110.16M Perf Week43.69%
Market Cap488.89M Forward P/E12.78 EPS next Y0.35 Insider Trans-8.41% Shs Float55.69M Perf Month6.47%
Income-198.64M PEG- EPS next Q-0.45 Inst Own48.18% Short Float2.94% Perf Quarter9.63%
Sales0.00M P/S- EPS this Y67.68% Inst Trans1.65% Short Ratio2.11 Perf Half Y148.04%
Book/sh1.61 P/B2.76 EPS next Y159.40% ROA-64.88% Short Interest1.64M Perf Year228.89%
Cash/sh1.82 P/C2.44 EPS next 5Y- ROE-74.48% 52W Range0.98 - 5.20 Perf YTD12.69%
Dividend Est.- P/FCF- EPS past 5Y- ROI-111.48% 52W High-14.53% Beta0.60
Dividend TTM- Quick Ratio4.47 Sales past 5Y0.00% Gross Margin- 52W Low352.97% ATR (14)0.43
Dividend Ex-Date- Current Ratio4.47 EPS Y/Y TTM39.62% Oper. Margin0.00% RSI (14)58.17 Volatility23.71% 9.95%
Employees94 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price9.67
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-64.02% Payout- Rel Volume1.93 Prev Close4.00
Sales Surprise- EPS Surprise-54.02% Sales Q/Q- EarningsMar 28 BMO Avg Volume775.98K Price4.44
SMA2020.80% SMA506.95% SMA20083.79% Trades Volume1,496,680 Change11.00%
Date Action Analyst Rating Change Price Target Change
Mar-26-24Upgrade Morgan Stanley Equal-Weight → Overweight $4 → $10
Dec-19-23Upgrade Morgan Stanley Underweight → Equal-Weight $1 → $4
May-01-23Initiated H.C. Wainwright Buy $5
Mar-28-24 01:53PM
07:00AM
Mar-22-24 03:28PM
03:04PM
Feb-05-24 04:02PM
12:35PM Loading…
Jan-29-24 12:35PM
Jan-12-24 12:00PM
Jan-03-24 07:00AM
Dec-23-23 05:29AM
Dec-19-23 11:52AM
Dec-18-23 07:00AM
Nov-13-23 10:21AM
Nov-10-23 08:35AM
Nov-09-23 04:01PM
Nov-02-23 04:01PM
04:01PM Loading…
Oct-31-23 04:01PM
Sep-11-23 07:00AM
Sep-06-23 08:17PM
07:00AM
Sep-05-23 07:00AM
Aug-29-23 01:13PM
Aug-15-23 05:45AM
Aug-11-23 06:43AM
Aug-10-23 04:01PM
Aug-03-23 04:01PM
Jul-27-23 04:01PM
Jul-17-23 02:15PM
07:00AM
Jun-26-23 07:00AM
Jun-22-23 01:07PM
07:00AM Loading…
07:00AM
Jun-01-23 07:00AM
May-23-23 06:25AM
May-11-23 04:01PM
May-04-23 04:01PM
Apr-25-23 04:01PM
07:00AM
Apr-14-23 09:35AM
Apr-12-23 07:00AM
Mar-30-23 04:01PM
Mar-28-23 04:58AM
Mar-24-23 06:41AM
Mar-23-23 04:01PM
Mar-22-23 04:30PM
Mar-16-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Feb-03-23 07:30AM
Jan-27-23 05:59PM
Jan-02-23 12:00PM
Dec-19-22 07:00AM
Dec-13-22 02:37PM
Dec-06-22 04:01PM
Nov-22-22 09:20PM
Nov-17-22 01:58PM
07:00AM
Nov-10-22 04:01PM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-24-22 04:01PM
Oct-17-22 02:37PM
Oct-13-22 04:26PM
04:01PM
Oct-12-22 04:01PM
Oct-03-22 08:05AM
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adimab, LLC10% OwnerJan 19 '24Sale3.955,000,00019,750,00021,687,906Jan 22 04:18 PM